Roivant Sciences Ltd
NASDAQ:ROIV

Watchlist Manager
Roivant Sciences Ltd Logo
Roivant Sciences Ltd
NASDAQ:ROIV
Watchlist
Price: 10.99 USD -2.74% Market Closed
Market Cap: 7.8B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+31%
Revenue
Forecast
+30%
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

ROIV Price Targets Summary
Roivant Sciences Ltd

Wall Street analysts forecast ROIV stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ROIV is 17.19 USD with a low forecast of 12.12 USD and a high forecast of 23.1 USD.

ROIV Lowest Forecast
Wall Street Target
12.12 USD
10% Upside
ROIV Average Forecast
Wall Street Target
17.19 USD
56% Upside
ROIV Highest Forecast
Wall Street Target
23.1 USD
110% Upside
Lowest
Price Target
12.12 USD
10% Upside
Average
Price Target
17.19 USD
56% Upside
Highest
Price Target
23.1 USD
110% Upside
Roivant Sciences Ltd Competitors:
Price Targets
S
002294
Shenzhen Salubris Pharmaceuticals Co Ltd
4% Upside
E
EMCURE
Emcure Pharmaceuticals Ltd
18% Upside
4528
Ono Pharmaceutical Co Ltd
27% Upside
NWRN
Newron Pharmaceuticals SpA
129% Upside
S
002294
Shenzhen Salubris Pharmaceuticals Co Ltd
4% Upside
E
EMCURE
Emcure Pharmaceuticals Ltd
18% Upside
4528
Ono Pharmaceutical Co Ltd
27% Upside
NWRN
Newron Pharmaceuticals SpA
129% Upside
VIRP
Virbac SA
16% Upside
T
600867
Tonghua Dongbao Pharmaceutical Co Ltd
19% Upside
128940
Hanmi Pharm Co Ltd
15% Upside
4886
ASKA Pharmaceutical Holdings Co Ltd
14% Upside

Revenue
Forecast

Revenue Estimate
Roivant Sciences Ltd

For the last 3 years the compound annual growth rate for Roivant Sciences Ltd's revenue is 74%. The projected CAGR for the next 4 years is 46%.

74%
Past Growth
46%
Estimated Growth
Estimates Accuracy
-8%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Roivant Sciences Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Roivant Sciences Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-14%
Average Miss
What are analyst estimates?

See Also

Summary
ROIV intrinsic value, competitors valuation, and company profile.
DCF Valuation
ROIV stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ROIV stock valuation using valuation multiples.
Wall Street Estimates
ROIV price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ROIV stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ROIV's stock price target?
Price Target
17.19 USD

According to Wall Street analysts, the average 1-year price target for ROIV is 17.19 USD with a low forecast of 12.12 USD and a high forecast of 23.1 USD.

What is Roivant Sciences Ltd's Revenue forecast?
Projected CAGR
46%

For the last 3 years the compound annual growth rate for Roivant Sciences Ltd's revenue is 74%. The projected CAGR for the next 4 years is 46%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 258,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.